Novavax, Inc. (NVAX) Receives Average Rating of “Hold” from Brokerages

Shares of Novavax, Inc. (NASDAQ:NVAX) have been assigned a consensus recommendation of “Hold” from the eleven research firms that are currently covering the stock, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating and three have assigned a buy rating to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $2.84.

A number of equities analysts have commented on the stock. S&P Equity Research dropped their target price on shares of Novavax from $1.81 to $1.35 in a research note on Wednesday, January 10th. B. Riley set a $10.00 target price on shares of Novavax and gave the stock a “buy” rating in a research note on Thursday, January 11th. Ladenburg Thalmann Financial Services upped their target price on shares of Novavax to $2.50 and gave the stock a “buy” rating in a research note on Thursday, January 11th. Zacks Investment Research downgraded shares of Novavax from a “hold” rating to a “sell” rating in a research note on Tuesday, January 16th. Finally, Citigroup downgraded shares of Novavax from a “buy” rating to a “neutral” rating and set a $1.00 target price on the stock. in a research note on Tuesday, December 19th.

Several institutional investors and hedge funds have recently made changes to their positions in NVAX. Raymond James Financial Services Advisors Inc. lifted its position in shares of Novavax by 49.8% in the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 89,697 shares of the biopharmaceutical company’s stock worth $103,000 after purchasing an additional 29,800 shares during the period. Teacher Retirement System of Texas lifted its position in shares of Novavax by 349.8% in the 4th quarter. Teacher Retirement System of Texas now owns 99,952 shares of the biopharmaceutical company’s stock worth $124,000 after purchasing an additional 77,733 shares during the period. Profund Advisors LLC lifted its position in shares of Novavax by 0.4% in the 2nd quarter. Profund Advisors LLC now owns 120,775 shares of the biopharmaceutical company’s stock worth $139,000 after purchasing an additional 455 shares during the period. Aperio Group LLC lifted its position in shares of Novavax by 121.1% in the 4th quarter. Aperio Group LLC now owns 115,323 shares of the biopharmaceutical company’s stock worth $143,000 after purchasing an additional 63,155 shares during the period. Finally, Voya Investment Management LLC lifted its position in shares of Novavax by 18.6% in the 2nd quarter. Voya Investment Management LLC now owns 138,270 shares of the biopharmaceutical company’s stock worth $159,000 after purchasing an additional 21,639 shares during the period. 35.71% of the stock is owned by hedge funds and other institutional investors.

Shares of Novavax (NVAX) traded down $0.02 during mid-day trading on Tuesday, reaching $1.99. 3,296,453 shares of the company’s stock were exchanged, compared to its average volume of 13,523,555. The company has a debt-to-equity ratio of -4.28, a current ratio of 3.31 and a quick ratio of 3.31. The company has a market cap of $627.23, a P/E ratio of -2.93 and a beta of 2.68. Novavax has a twelve month low of $0.73 and a twelve month high of $2.32.

WARNING: This article was originally reported by American Banking News and is the property of of American Banking News. If you are viewing this article on another site, it was copied illegally and republished in violation of United States & international copyright and trademark laws. The legal version of this article can be read at https://www.americanbankingnews.com/2018/02/13/novavax-inc-nvax-receives-average-rating-of-hold-from-brokerages.html.

Novavax Company Profile

Novavax, Inc is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases.

Analyst Recommendations for Novavax (NASDAQ:NVAX)

Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply